News Headlines Article

Hayward-made diabetes treatment beats $6B Merck drug in head-to-head trial
San Diego Business Journal

A drug for type 2 diabetes that’s manufactured in Hayward showed its tiny drug pump worked better in a head-to-head comparison with the leading once-a-day pill for the disease, Januvia, which generated more than $6 billion in revenue last year. Intarcia, a privately-held firm based in Boston’s Seaport District, said the trial showed patients who had its tiny ITCA 650 implanted under their skin saw double the reduction in a type of hemoglobin tied to the disease after one year than patients taking Januvia, by Merck & Co. (NYSE: MRK).